Contineum Therapeutics (CTNM) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
30 Apr, 2026Executive summary
Annual meeting scheduled for June 26, 2026, to be held virtually for stockholders of record as of April 27, 2026.
Proxy materials and annual report are available online, with options to request paper or email copies by June 16, 2026.
Voting matters and shareholder proposals
Election of three Class II directors to serve until the 2029 annual meeting or until successors are appointed.
Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Provision to conduct any other business properly brought before the meeting or adjournment.
Board of directors and corporate governance
Nominees for Class II director positions are Evert Schimmel Pennink, Lori M. Lyons-Williams, and Diego Miralles, M.D.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Contineum Therapeutics
- Multiple clinical milestones expected in the next 12 months for neuroscience and immunology programs.CTNM
Cantor Global Healthcare Conference 20259 Jul 2026 - Multiple Phase II trials and strong funding position drive momentum in neuroscience and immunology.CTNM
7th Annual Evercore ISI HealthCONx Healthcare Conference8 Jul 2026 - Multiple clinical milestones ahead for neuroscience and immunology assets, with strong funding.CTNM
Baird Global Healthcare Conference 20251 Jul 2026 - PIPE-791 advances in IPF with strong differentiation, robust pipeline, and solid financial runway.CTNM
Goldman Sachs 47th Annual Global Healthcare Conference 20269 Jun 2026 - PIPE-791 shows strong safety, efficacy signals, and differentiation in IPF and pain studies.CTNM
RBC Capital Markets Global Healthcare Conference 202619 May 2026 - PIPE-791 and PIPE-307 advance in IPF, pain, and MDD, with strong financial backing and J&J partnership.CTNM
Corporate presentation5 May 2026 - Q1 2026 net loss narrowed to $14.5M, with $246.3M in cash and key clinical programs advancing.CTNM
Q1 20265 May 2026 - Election of directors and auditor ratification highlight a focus on governance and transparency.CTNM
Proxy filing30 Apr 2026 - PIPE-791 and PIPE-307 advance as best-in-class assets, with major catalysts expected this year.CTNM
Leerink Global Healthcare Conference 202611 Mar 2026